|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||20.06 - 21.35|
|52-week range||16.50 - 21.54|
|Beta (5Y monthly)||0.37|
|PE ratio (TTM)||17.82|
|Forward dividend & yield||1.09 (5.43%)|
|Ex-dividend date||18 Nov 2021|
|1y target est||N/A|
– New preclinical findings generated through in vitro testing of sotrovimab againstthe complete pseudo-virus updated to bioRxiv – Data build on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19 – – Sotrovimab is authorized and available for the treatment of early COVID-19 in the US and multiple countries around the world – LONDON and SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechno
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.
With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.